A recent report revealed that proteasome inhibitor MG132/bortezomib suppressed AGR2 expression in an ER stress-independent manner and proteasome inhibitor-induced AGR2 degradation via activation of autophagy in lung cancer [58]. This evidence concerns the gene AGR2 and lung carcinoma.